Loading...
Loading...
LUMO| Name | Value |
|---|---|
| Revenues | 691.0K |
| Cost of Revenue | 9.0K |
| Gross Profit | 682.0K |
| Operating Expense | 8,726.0K |
| Operating I/L | -8,035.0K |
| Other Income/Expense | 689.0K |
| Interest Income | 570.0K |
| Pretax | -7,346.0K |
| Income Tax Expense | -689.0K |
| Net Income/Loss | -6,657.0K |
Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company specializing in the development and commercialization of therapeutics for rare diseases. Their lead therapeutic candidate, LUM-201, is an oral growth hormone secretagogue ibutamoren currently in Phase 2 clinical trial for pediatric growth hormone deficiency and other rare endocrine disorders.
